Lilly's Olumiant Is First Drug FDA Approved For Alopecia Areata

The FDA approved baricitinib for the hair loss disorder despite safety concerns with JAK inhibitors. It carries the same warnings on risk of CV events and malignancy as the others in the class.

trophy
Lilly is the first to market with a drug for alopecia areata • Source: Shutterstock

The US Food and Drug Administration approved Eli Lilly and Company's JAK inhibitor Olumiant (baricitinib) for the treatment of severe alopecia areata, marking the first systemic treatment approved for the disorder that can cause patchy baldness. With the 13 June approval, Lilly beat a close rival, Pfizer Inc., to the market.

The FDA approved Olumiant for rheumatoid arthritis in 2018, but the drug has faced a challenging commercial market due to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip